Floatz logo

177lu-ctr-fapi

Pancreatic Ductal Adenocarcinoma (PDAC)

Xijing HospitalN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
73/ 100

Competitive context

282 Active assets in the Pancreatic Ductal Adenocarcinoma (PDAC) cohort.

Asset / SponsorPhaseRating
Irinotecan
NRG Oncology
Phase 3BB
Daraxonrasib
Revolution Medicines, Inc.
Phase 3BB
IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER
OHSU Knight Cancer Institute
Phase 2BB
Rmc-6236
Tango Therapeutics, Inc.
Phase 3BB
S-1
Genentech, Inc.
Phase 2BB

View all 50 →

Same molecule, other indications

177lu-ctr-fapi is also rated in:

metastatic neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
pancreatic neoplasmDormant
C
Indicative ·
33 / 100
View asset →
gastric adenocarcinomaDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →